Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound chemotherapy medicament for treating liver cancer and multi-drug resistance tumor

A chemotherapeutic drug and multi-drug resistance technology, applied in the field of biomedicine, can solve problems such as easy induction

Inactive Publication Date: 2009-08-26
曾庆平
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Another disadvantage of artemisinin as a tumor chemotherapy drug is that it is easy to induce the expression of antioxidant enzymes (mainly glutathione peroxidase and catalase) genes in tumor cells, thereby counteracting the effect of artemisinin on carbon dioxide. The killing effect of free radicals on tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] For adult liver cancer patients with a body weight of 50-80kg or patients resistant to other chemotherapy drugs, take the medicine once a day for 4 weeks. The dose of artemether was 200 mg, the dose of diethyl maleate, N-ethylmaleimide, or butysulfinimide was 80 mmol, and the doses of mercaptosuccinic acid and 3-aminotriazole were each 20mg and 50mg. For minor patients, reduce the dosage by half or follow the doctor's advice.

Embodiment 2

[0018] For adult liver cancer patients weighing 50-80kg or patients resistant to other chemotherapy drugs, intravenous injection twice a week for 4 consecutive weeks, the drug contains dihydroartemisinin, artemisinin succinate, artemisinin ether or artemisinin The dose of artemether is 300 mg, the dose of diethyl maleate, N-ethylmaleimide, or butyrsulfinimide is 100 mmol, and the dose of mercaptosuccinic acid and 3-aminotriazole is 30 mg each and 60mg. For minor patients, reduce the dosage by half or follow the doctor's advice.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses medicinal application of a compound chemotherapy medicament of artemisinins (dihydroartemisinin, artemisinin succinate, artemisinin methyl ether, or artemisinin ethyl ether), glutathione depleting agents (diethyl maleate, N-ethyl-maleimide or buthionine sulfoximine) and antioxidant enzyme inhibitors (mercapto-succinic acid and 3-amino-triazole), wherein the compound chemotherapy medicament can be used as the compound chemotherapy medicament for liver cancer and multi-drug resistance tumor with efficient, quick effect, low toxicity and low cost. Liver cancer and multi-drug resistance tumor patients orally take the medicament or are applied by intravenous injection; the everyday treatment dosage comprises 1 to 100 milligrams per kilogram of the dihydroartemisinin, the artemisinin succinate, the artemisinin methyl ether or the artemisinin ethyl ether, 1 to 80 millimoles per kilogram of the diethyl maleate, the N-ethyl-maleimide or the buthionine sulfoximine, 1 to 50 milligrams per kilogram of the mercapto-succinic acid, and 1 to 50 milligrams per kilogram of the 3-amino-triazole; the medicament can be used once or repeatedly; and after the treatment, the tumor can disappear or the proliferation of the tumor can be controlled, so the patients can live for a long time and work normally.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to compound chemotherapeutic drugs of artemisinin, glutathione depleting agent and antioxidant enzyme inhibitor for treating liver cancer and multidrug-resistant tumors. Background technique [0002] Malignant tumor is the second deadliest disease after cardiovascular and cerebrovascular diseases. According to the report of the World Health Organization in 1996, there were as many as 9 million new cancer cases worldwide, of which 1.6 million were in my country. According to statistics from the American Cancer Society, in 2002 the number of people who died of cancer worldwide was 6.7 million, and by 2020, this number will reach 10.3 million. The incidence of liver cancer among males in my country ranks first in the world, with 36.7 per 100,000 people. The best treatment for liver cancer is surgical resection, but because the early symptoms of liver cancer patients a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/357A61P35/00A61P1/16A61K31/194A61K31/198A61K31/402A61K31/4196
Inventor 曾庆平
Owner 曾庆平
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com